Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826502PMC
http://dx.doi.org/10.1136/bcr-2023-256644DOI Listing

Publication Analysis

Top Keywords

autoimmune myelofibrosis
4
myelofibrosis clinical
4
clinical histological
4
histological efficacy
4
efficacy ciclosporin
4
ciclosporin treatment
4
autoimmune
1
clinical
1
histological
1
efficacy
1

Similar Publications

Primary myelofibrosis (PMF) is an uncommon chronic myeloproliferative disorder that is commonly associated with Janus kinase 2 (JAK-2), calreticulin (CALR), or thrombopoietin receptor (MPL) mutations. Pre-fibrotic PMF (also known as pre-PMF or early PMF) is a subtype of PMF that is defined by a lower grade of fibrosis. In this report, we present a rare case of warm autoimmune hemolytic anemia (wAIHA) associated with pre-PMF.

View Article and Find Full Text PDF

A Case of Autoimmune Myelofibrosis Associated With Autoimmune Hepatitis.

J Hematol

August 2024

Saskatoon Cancer Center, Saskatchewan Cancer Agency, and College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Autoimmune myelofibrosis (AIMF) is a distinct, underrecognized, and rare cause of bone marrow fibrosis. It carries a favorable outcome and responds well to immunosuppression. Systemic lupus erythematosus is the most common association with AIMF, but there are other cases of associated autoimmune disorders defined in the literature.

View Article and Find Full Text PDF
Article Synopsis
  • TAFRO syndrome is a systemic inflammatory disorder characterized by symptoms like thrombocytopenia, fever, and organomegaly, resembling either a connective tissue or autoimmune disease, and is linked to idiopathic multicentric Castleman disease (iMCD).
  • A young Chinese female patient initially thought to have mixed connective tissue disease showed symptoms like joint pain and kidney issues, leading to a diagnosis of TAFRO syndrome after various tests, including a lymph node biopsy.
  • Following chemotherapy treatment, the patient's symptoms improved significantly, indicating that targeting inflammatory factors with treatments like corticosteroids or chemotherapy is crucial for managing this syndrome.
View Article and Find Full Text PDF
Article Synopsis
  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can cause various organ issues, including autoimmune peripheral cytopenia, which can lead to a rare condition known as autoimmune myelofibrosis (AIMF).
  • A case was reported involving a 34-year-old woman with AIMF, who exhibited symptoms like gingival bleeding, joint pain, and swelling, along with lab findings indicative of SLE.
  • There is limited research on the link between AIMF and SLE; however, recognizing this connection is important in case of uncontrolled cytopenia in SLE patients, and treatment remains aligned with standard SLE management.
View Article and Find Full Text PDF

Small molecule drug discovery targeting the JAK-STAT pathway.

Pharmacol Res

June 2024

School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Queensland 4072, Australia. Electronic address:

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway functions as a central hub for transmitting signals from more than 50 cytokines, playing a pivotal role in maintaining hematopoiesis, immune balance, and tissue homeostasis. Dysregulation of this pathway has been implicated in various diseases, including immunodeficiency, autoimmune conditions, hematological disorders, and certain cancers. Proteins within this pathway have emerged as effective therapeutic targets for managing these conditions, with various approaches developed to modulate key nodes in the signaling process, spanning from receptor engagement to transcription factor activation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!